Collegium Appoints Vikram Karnani as Chief Executive Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Collegium Pharmaceutical (COLL) PT Lowered to $40 at Jefferies
November 11, 2024 3:55 PM ESTJefferies analyst Glen Santangelo lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $40.00 (from $44.00) while maintaining a Buy rating.
The analyst comments "Model update post 3Q results. Overall, we remain encouraged by momentum in the underlying pain portfolio, coupled with new LT... More
